Solasia Pharma K.K
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial d… Read more
Solasia Pharma K.K (9SO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.158x
Based on the latest financial reports, Solasia Pharma K.K (9SO) has a cash flow conversion efficiency ratio of -0.158x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-310.00 Million) by net assets (€1.97 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Solasia Pharma K.K - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Solasia Pharma K.K's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Solasia Pharma K.K Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Solasia Pharma K.K ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ANGLE plc
OTCQX:ANPCF
|
-0.385x |
|
Firma Oponiarska DĘBICA SA
WAR:DBC
|
0.032x |
|
Lotus Bakeries NV
PINK:LOTBY
|
0.084x |
|
Cardlytics Inc
NASDAQ:CDLX
|
-0.374x |
|
Mithril Silver and Gold Ltd
AU:MTH
|
-0.013x |
|
Kpx Green Chem
KO:083420
|
0.108x |
|
Fosterville South Exploration Ltd
OTCQX:FSXLF
|
-0.083x |
|
U.S. GoldMining Inc. Common stock
NASDAQ:USGO
|
-0.754x |
Annual Cash Flow Conversion Efficiency for Solasia Pharma K.K (2016–2024)
The table below shows the annual cash flow conversion efficiency of Solasia Pharma K.K from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €1.16 Billion | €-1.03 Billion | -0.894x | -35.12% |
| 2023-12-31 | €1.88 Billion | €-1.24 Billion | -0.661x | +15.12% |
| 2022-12-31 | €2.66 Billion | €-2.07 Billion | -0.779x | +18.50% |
| 2021-12-31 | €2.59 Billion | €-2.47 Billion | -0.956x | -25.17% |
| 2020-12-31 | €3.65 Billion | €-2.79 Billion | -0.764x | -537.98% |
| 2019-12-31 | €6.92 Billion | €-828.00 Million | -0.120x | +63.48% |
| 2018-12-31 | €7.09 Billion | €-2.32 Billion | -0.328x | -123.39% |
| 2017-12-31 | €6.21 Billion | €-911.00 Million | -0.147x | -8.58% |
| 2016-12-31 | €3.43 Billion | €-464.00 Million | -0.135x | -- |